Stock 603229 ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Zhejiang Ausun Pharmaceutical Co., Ltd.

Equities

603229

CNE100002XK2

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
11.61 CNY +2.38% Intraday chart for Zhejiang Ausun Pharmaceutical Co., Ltd. +16.92% -12.11%
26/04 Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
26/04 Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. Stock Zhejiang Ausun Pharmaceutical Co., Ltd.
-12.11% 951M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 699B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.77% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 154B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 603229 Stock
  4. Ratings Zhejiang Ausun Pharmaceutical Co., Ltd.